Lezhi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lezhi Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Mining Liang
Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China
2 shared publicationsJianjian Wang
Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China
1 shared publicationLi He
Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China
1 shared publicationQingming Wang
Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publicationQiongni Chen
Department of Nursing, The Second Xiangya Hospital, Central South University, Hunan Province, Changsha, China
1 shared publicationWei Yang
Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 27 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (9) , 14516-14524
Impact of diabetes on the risk of bedsore in patients undergoing surgery: an updated quantitative analysis of cohort studies
Impact of diabetes on the risk of bedsore in patients undergoing surgery: an updated quantitative analysis of cohort studies
- 27 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (9) , 14516-14524
Open AccessImpact of diabetes on the risk of bedsore in patients undergoing surgery: an updated quantitative analysis of cohort studies
Impact of diabetes on the risk of bedsore in patients undergoing surgery: an updated quantitative analysis of cohort studies
- Open Access
- 18 November 2016
- Published by Wiley in International Journal of Cancer
- Vol. 140 (5) , 1068-1081
Effects of statins on cancer mortality and progression: A systematic review and meta‐analysis of 95 cohorts including 1,111,407 individuals
Statins have been implicated in the regulation of cell proliferation, apoptosis and tumor progression in cancer patients and statin use at the time of cancer diagnosis has been reported to be associated with reduced cancer risk and improved survival, irrespective of concomitant anti‐cancer therapy. A systematic literature search of relevant databases through May 2015 was conducted to identify studies assessing the prognostic impact of statin use on prognostic outcomes in cancer patients. Literature search identified 95 cohort studies that met the inclusion criteria. A meta‐analysis of 55 articles showed that statin use was significantly associated with decreased risk of all‐cause mortality (HR 0.70, 95% Cl 0.66 to 0.74) compared with nonusers. The observed pooled estimates were retained for cancer‐specific mortality (HR 0.60, 95% Cl 0.47 to 0.77), progression‐free survival (HR 0.67, 95% Cl 0.56 to 0.81), recurrence‐free survial (HR 0.74, 95% Cl 0.65 to 0.83) and disease‐free survival (HR 0.53, 95% Cl 0.40 to 0.72). These associations almost remained consistent across those outcomes when stratified by publication type, tumour location, study design, sample size, initiation of statins, disease stage, research country, follow‐up duration or research hospital involved. Subgroup analyses according to initiation of statins showed postdiagnosis statin users (HR 0.65, 95% Cl 0.54 to 0.79) gained significantly more recurrence‐free survival benefit than prediagnosis statin users (HR 0.86, 95% Cl 0.77 to 0.96) (p for interaction = 0.018). Statin therapy has potential survival benefit for patients with malignancy. Further large‐scale prospective studies emphasising survival outcomes of individual cancer type are strongly encouraged.
- 18 November 2016
- Published by Wiley in International Journal of Cancer
- Vol. 140 (5) , 1068-1081
Open AccessEffects of statins on cancer mortality and progression: A systematic review and meta‐analysis of 95 cohorts including 1,111,407 individuals
Statins have been implicated in the regulation of cell proliferation, apoptosis and tumor progression in cancer patients and statin use at the time of cancer diagnosis has been reported to be associated with reduced cancer risk and improved survival, irrespective of concomitant anti‐cancer therapy. A systematic literature search of relevant databases through May 2015 was conducted to identify studies assessing the prognostic impact of statin use on prognostic outcomes in cancer patients. Literature search identified 95 cohort studies that met the inclusion criteria. A meta‐analysis of 55 articles showed that statin use was significantly associated with decreased risk of all‐cause mortality (HR 0.70, 95% Cl 0.66 to 0.74) compared with nonusers. The observed pooled estimates were retained for cancer‐specific mortality (HR 0.60, 95% Cl 0.47 to 0.77), progression‐free survival (HR 0.67, 95% Cl 0.56 to 0.81), recurrence‐free survial (HR 0.74, 95% Cl 0.65 to 0.83) and disease‐free survival (HR 0.53, 95% Cl 0.40 to 0.72). These associations almost remained consistent across those outcomes when stratified by publication type, tumour location, study design, sample size, initiation of statins, disease stage, research country, follow‐up duration or research hospital involved. Subgroup analyses according to initiation of statins showed postdiagnosis statin users (HR 0.65, 95% Cl 0.54 to 0.79) gained significantly more recurrence‐free survival benefit than prediagnosis statin users (HR 0.86, 95% Cl 0.77 to 0.96) (p for interaction = 0.018). Statin therapy has potential survival benefit for patients with malignancy. Further large‐scale prospective studies emphasising survival outcomes of individual cancer type are strongly encouraged.